Skip to main content
logo
Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
2.010
+0.140 (7.49%)
At close: Jul 14, 2025, 4:00 PM
2.020
+0.010 (0.50%)
After-hours: Jul 14, 2025, 4:16 PM EDT

Iovance Biotherapeutics Revenue

Iovance Biotherapeutics had revenue of $49.32M in the quarter ending March 31, 2025, with 6,798.46% growth. This brings the company's revenue in the last twelve months to $212.68M, up 11,070.12% year-over-year. In the year 2024, Iovance Biotherapeutics had annual revenue of $164.07M with 13,698.99% growth.

Revenue (ttm)
$212.68M
Revenue Growth
+11,070.12%
P/S Ratio
2.67
Revenue / Employee
$253,794
Employees
838
Market Cap
671.21M

Revenue Chart

Revenue History

Fiscal Year End Revenue Change Growth
Dec 31, 2024 164.07M 162.88M 13,698.99%
Dec 31, 2023 1.19M - -
Dec 31, 2022 - - -
Dec 31, 2021 - - -
Dec 31, 2020 - - -
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 410.06B
Johnson & Johnson 89.33B
Merck & Co. 63.92B
AbbVie 57.37B
AstraZeneca 54.98B
Novartis AG 53.22B
Eli Lilly and Company 49.00B
Novo Nordisk 43.92B
Revenue Rankings

IOVA News

More News